In this prospective, multicenter trial, 140 cirrhotic patients with no previous upper gastrointestinal bleeding and with esophageal varices endoscopically judged to be at high risk of hemorrhage were randomized to receive either sclerotherapy or conservative treatment for the prevention of first var
Prophylactic sclerotherapy for esophageal varices: Long-term results of a single-center trial
โ Scribed by Dr David R. Triger; Howard L. Smart; Shorland W. Hosking; Alan G. Johnson
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 691 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
Survival after prophylactic sclerotherapy was assessed in a single-center study involving 99 cirrhotic (41 alcoholic) patients enrolled over 8-yr. The wedged hepatic vein pressure gradient was measured; those with pressure 3 12 mm Hg were randomized to receive sclerotherapy or no treatment. The rest were not randomized. Patients in all three groups who bled were treated with emergency endoscopy and sclerotherapy. Stratification according to presence of ascites was also undertaken. Median follow-up was 61 mo (range = 14 to 107 mo). Survival among unrandomized patients was significantly longer than among randomized patients (p < 0.006), but there was no significant difference between those treated by sclerotherapy and the controls (p = 0.27). Alcoholic cirrhotic patients undergoing sclerotherapy had better 2-yr survival than did the controls (80% vs. 43%; p = 0.091, but this benefit was not sustained at 5 yr. Survival in the nonalcoholic patient groups was identical. Only 10 of 50 deaths were caused by variceal bleeding. Forty-eight percent of patients with large varices bled, compared with 20% of patients with small varices. Wedged hepatic vein pressure < 12 mm Hg accurately identified alcoholic patients at low risk of variceal bleeding but not nonalcoholic patients. Only four episodes of variceal bleeding were attributable to elective sclerotherapy.
We conclude that in our population, prophylactic sclerotherapy alone does not improve survival. The discrepancy in survival between alcoholic and nonalcoholic cirrhotic patients suggests that factors other than variceal hemorrhage may be responsible for the difference. (HEPATOLOCY 1991: 13:117-123.)
Bleeding from esophageal varices is said to be a major cause of death among patients with cirrhosis and portal hypertension. The notion that this could be prevented by decompression shunt surgery was tested by a series of controlled trials during the early 1970s. Although the incidence of bleeding was effectively reduced, no substantial improvement in survival could be achieved. The increased incidence of severe encephalopathy, liver
๐ SIMILAR VOLUMES
Long-term follow-up (median: 37 months; range: 19 to 68) of the 116 patients (66 sclerotherapy, 60 control group) entered into a controlled trial of endoscopic variceal sclerotherapy has shown a total of 18 deaths in the sclerotherapy group, including five from variceal bleeding compared with 32 dea
This trial was carried out to assess the value of propranolol for the prevention of recurrent variceal bleeding in patients with well-compensated cirrhosis. We also compared propranolol therapy to long-term injection sclerotherapy. One hundred and eight patients, in whom the original variceal hemorr
AND SHOU-DONG LEE'" Endoscopic variceal injection sclerotherapy (EVS) has been well accepted as the procedure of choice for the treatment. of acute esophageal variceal bleeding and serves as the standard for comparison of new ther-